Fate Therapeutics (NASDAQ:FATE)‘s stock had its “buy” rating reaffirmed by analysts at Raymond James Financial in a report released on Tuesday.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine lowered Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd. BMO Capital Markets restated a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research report on Thursday, November 2nd. Finally, Leerink Swann restated an “outperform” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research report on Friday, September 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Fate Therapeutics currently has an average rating of “Buy” and an average price target of $6.79.

Shares of Fate Therapeutics (NASDAQ:FATE) opened at $4.14 on Tuesday. Fate Therapeutics has a 52-week low of $2.40 and a 52-week high of $5.68. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.95 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Fate Therapeutics will post -0.99 EPS for the current year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel D. Shoemaker sold 13,225 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. Corporate insiders own 10.88% of the company’s stock.

Several hedge funds have recently made changes to their positions in FATE. Morgan Stanley raised its stake in shares of Fate Therapeutics by 9.8% during the 1st quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after buying an additional 54,615 shares during the period. Renaissance Technologies LLC raised its stake in shares of Fate Therapeutics by 40.9% during the 1st quarter. Renaissance Technologies LLC now owns 295,700 shares of the biopharmaceutical company’s stock worth $1,345,000 after buying an additional 85,800 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Fate Therapeutics by 479.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 144,053 shares of the biopharmaceutical company’s stock worth $655,000 after buying an additional 119,200 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Fate Therapeutics in the 2nd quarter valued at $214,000. Finally, Rhumbline Advisers acquired a new position in Fate Therapeutics in the 2nd quarter valued at $133,000. 60.97% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Fate Therapeutics (FATE) Earns “Buy” Rating from Raymond James Financial” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/fate-therapeutics-fate-earns-buy-rating-from-raymond-james-financial/1759235.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.